Clinical trials: Delayed Gastric Emptying
Chronic Unexplained Nausea and Vomiting, Gastroparesis
Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
The hypothesis of this pilot study is that nVNS will result in relief of nausea by modulation of vagal nerve activity. nVNS is the first non-invasive, handheld medical device applied on the side of the neck and sends gentle…
- Trial name
- nVNS (NCT04857281)
- Testing
- nVNS (gammaCore)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Johns Hopkins University
Gastroparesis
Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)
This study is to evaluate the safety and effectiveness of gastric stimulation in the reduction of nausea and vomiting in patients with gastroparesis using an approved Humanitarian device.
- Trial name
- NCT00157755
- Testing
- Enterra Therapy
- Where
- 6 sites in United States
- Volunteers
- 87 people
- Sponsor
- MedtronicNeuro
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.
- Trial name
- NCT04303195
- Testing
- NG101
- Where
- 83 sites in United States
- Volunteers
- 161 people
- Sponsor
- Neurogastrx, Inc.
Gastroparesis
Buspirone for Early Satiety and Symptoms of Gastroparesis
This study evaluates whether the study medication, buspirone, an antianxiety drug, improves the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately severe symptoms of fullness and/or…
- Trial name
- BESST (NCT03587142)
- Testing
- Buspirone
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03285308
- Testing
- Relamorelin
- Where
- 216 sites in United States, Australia and 12 more
- Volunteers
- 336 people
- Sponsor
- Allergan
Patients With Gastroparesis Who Have Failed Standard Therapy
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
To provide oral domperidone to patients between the ages of 18 and 60 years of age, according to the investigator's judgment, a prokinetic effect is needed for the relief of severe gastroparesis.
- Trial name
- NCT01711918
- Testing
- Domperidone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ron Schey
Gastroparesis
Enterra Therapy Gastric Stimulation System
Enterra Therapy Gastric Simulation System (Enterra Therapy) is indicated for the treatment of patients with long term, uncontrolled (not helped by medication) nausea and vomiting from gastroparesis of diabetic or idiopathic…
- Trial name
- Enterra (NCT00556166)
- Testing
- Enterra Therapy Gastric Stimulator
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Type 2 Diabetes Mellitus
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
This study will evaluate whether bile acids are able to increase insulin sensitivity and enhance glycemic control in T2DM patients, as well as exploring the mechanisms that enhance glycemic control.
- Trial name
- NCT02033876
- Testing
- Ursodiol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Gastroparesis
Diabetic Gastroparesis Study 05
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 [NCT03420781] or RLM-MD-04 [NCT03383146] study and to provide treatment for these…
- Trial name
- NCT03786380
- Testing
- Relamorelin 10 μg
- Where
- 486 sites in United States, Argentina and 28 more
- Volunteers
- 202 people
- Sponsor
- Allergan
Gastroparesis
Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)
- Trial name
- NCT01135186
- Testing
- sapropterin dihydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University